KRAS G13D peptide, 25 mer

This 25-amino acid peptide corresponds to the immunogenic KRAS G13D oncogenic mutation, functioning as an immune potentiator for vaccine research. It is applied in preclinical studies to investigate T-cell responses and immunotherapeutic strategies targeting KRAS-driven cancers in both in vitro and in vivo models.